Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The role of regulatory T cells in blood during acute heart transplant rejection
EF 2020-21
Résumé
Acute cellular rejection poses a significant challenge in fully realizing the potential of heart transplantation to cure end-stage heart failure. In order to prevent organ rejection, patients receive maintenance immunosuppression, and are prescribed even higher doses or additional immunosuppressants when rejection is diagnosed. However, these drugs produce a myriad of serious side effects, including cardiovascular complications, infection and cancer. Therefore, a radically different and more specific approach to treating and preventing acute rejection is needed to allow heart transplantation to become a true cure. Therapies based on immune-modulating regulatory T cells (Treg) can protect the allograft from the host's immune system while still allowing for normal immune function. However, the activity of Tregs during acute rejection is unknown and thus their therapeutic applicability in the context of heart transplantation has not been explored. In this proposal, I will investigate the changes in Treg activities during acute cellular rejection by quantifying 46 genes in blood that track acute cellular rejection trajectory and Treg activities. These biomarkers have been developed and validated in a large cohorts of patient samples; in the case of the rejection panel, the discovery work alone included more than 160 heart transplant patients from 7 hospitals across Canada. Results from this work will provide insights into Treg biology during acute cellular rejection, and may provide a complementary diagnostic platform for future investigations of using Treg-based therapies for creating personalized, longer-term immune management strategies for heart transplant patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449457
Name
Niusha Shanay
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of regulatory T cells in blood during acute heart transplant rejection
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Cellular Rejection; Bioinformatics; Biomarkers; Gene Expression; Graft Rejection; Heart Transplantation; Immunosuppression; Multivariate Statistics; Nanostring Ncounter Assay; Regulatory T Cell
Abstract
Acute cellular rejection poses a significant challenge in fully realizing the potential of heart transplantation to cure end-stage heart failure. In order to prevent organ rejection, patients receive maintenance immunosuppression, and are prescribed even higher doses or additional immunosuppressants when rejection is diagnosed. However, these drugs produce a myriad of serious side effects, including cardiovascular complications, infection and cancer. Therefore, a radically different and more specific approach to treating and preventing acute rejection is needed to allow heart transplantation to become a true cure. Therapies based on immune-modulating regulatory T cells (Treg) can protect the allograft from the host's immune system while still allowing for normal immune function. However, the activity of Tregs during acute rejection is unknown and thus their therapeutic applicability in the context of heart transplantation has not been explored. In this proposal, I will investigate the changes in Treg activities during acute cellular rejection by quantifying 46 genes in blood that track acute cellular rejection trajectory and Treg activities. These biomarkers have been developed and validated in a large cohorts of patient samples; in the case of the rejection panel, the discovery work alone included more than 160 heart transplant patients from 7 hospitals across Canada. Results from this work will provide insights into Treg biology during acute cellular rejection, and may provide a complementary diagnostic platform for future investigations of using Treg-based therapies for creating personalized, longer-term immune management strategies for heart transplant patients.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Niusha, Shanay
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~